Skip to content
Clinical Trials – home
AustriaBack to Austria

Clinical trials in Steyr – page 14

449 clinical trials in Steyr, Austria. Every trial is listed in the EU Clinical Trials Register and updated daily.

Steyr at a glance
449
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

449 trials in Steyr

Open in trial search

Study on the Long-term Safety and Tolerability of Azetukalner for Patients with Epilepsy, Including Focal-onset and Primary Generalized Tonic-Clonic Seizures

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Azetukalner
  • Sponsor:Xenon Pharmaceuticals Inc.

Study on Monitoring Untreated Multiple Myeloma in Patients Using Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone or a New Drug Combination

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Emn Trial Office S.r.l. Impresa Sociale

Study on Venetoclax and Obinutuzumab for Adults with Recurring Chronic Lymphocytic Leukemia

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Obinutuzumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study on Lutetium (177Lu) Vipivotide Tetraxetan to Delay Recurrence in Adult Men with PSMA-Positive Oligometastatic Prostate Cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Gozetotide
  • Sponsor:Novartis Pharma AG

Study Comparing Telisotuzumab Vedotin and Docetaxel for Adults with Previously Treated Non-Squamous Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study on Venetoclax and Drug Combination for Adults with Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome with Excess Blasts-2

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Cytarabine
  • Sponsor:Universitaetsklinikum Ulm AöR

Study on Long-term Safety and Efficacy of Efgartigimod PH20 SC in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx

Study on Vinblastine for Children and Adolescents with Standard Risk ALK-Positive Anaplastic Large Cell Lymphoma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years
  • Substances:Vinblastine Sulfate
  • Sponsor:GPOH gGmbH

Ewing's sarcoma

Recruiting

Study on Ewing Sarcoma Treatment with Vinorelbine and Drug Combination for Patients with Primary and Disseminated Disease

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years
  • Substances:Cyclophosphamide
  • Sponsor:GPOH gGmbH

Study on Ivosidenib for Patients with Previously Treated Advanced or Metastatic Cholangiocarcinoma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Ivosidenib
  • Sponsor:Servier Affaires Medicales

Study on the Safety and Effectiveness of TransCon CNP for Children and Adolescents with Achondroplasia

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:0–17 years
  • Substances:Navepegritide
  • Sponsor:Ascendis Pharma Growth Disorders A/S

Study on the Effects of XEN1101 and Placebo for Patients with Primary Generalized Tonic-Clonic Seizures

Investigational
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Azetukalner
  • Sponsor:Xenon Pharmaceuticals Inc.

Other cities in Austria

The busiest research cities in the country

All 48 cities in Austria

Clinical research in Steyr

What the registry says about research in the country

01 Oncology - Blood Cancers

Innovative research focusing on multiple myeloma treatment approaches, including maintenance therapy post stem-cell transplantation and comparing different administration methods for targeted therapies. Studies also investigate new treatments for Hodgkin Lymphoma with emphasis on reducing toxicity while maintaining efficacy.

  • Multiple Myeloma Treatments
  • Hodgkin Lymphoma Therapy
  • Stem Cell Transplantation

Advanced clinical research evaluating novel drug combinations and administration routes to improve patient outcomes.

02 Breast Cancer Research

Comprehensive studies examining treatments for ER-positive, HER2-negative breast cancer, including both early-stage and advanced disease. Research focuses on novel therapeutic agents and extended treatment strategies to prevent recurrence.

  • Early Breast Cancer Treatment
  • Advanced Breast Cancer Therapy
  • Endocrine Therapy Innovation

Trials aim to improve current treatment standards and evaluate new therapeutic options for breast cancer patients.

03 Pain Management Studies

Extensive research into chronic pain conditions, including diabetic polyneuropathy, post-operative neuropathy, and chronic back pain. Studies evaluate new treatment approaches for various types of neuropathic and musculoskeletal pain.

  • Neuropathic Pain Treatment
  • Chronic Back Pain Management
  • Post-operative Pain Control

Investigations focus on developing effective add-on treatments for chronic pain conditions to improve patient quality of life.

04 Pancreatic Cancer Research

Advanced studies in metastatic pancreatic ductal adenocarcinoma, evaluating novel combination therapies to improve survival rates. Research focuses on comparing standard treatments with new therapeutic approaches.

  • Metastatic Disease Treatment
  • Combination Therapy Assessment
  • Survival Rate Improvement

Clinical trials aim to enhance treatment outcomes for patients with advanced pancreatic cancer.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.